查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1404679

微生物 API 市场规模、份额、趋势分析报告：按宿主、按类型、按位置、按分子、按最终用途、按地区、细分市场预测，2023-2030 年

Microbial API Market Size, Share & Trends Analysis Report By Hose (Mammalian, Bacterial, Fungal), By Type (Antibody, Peptide, Protein), By Site, By Molecule, By End-use, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10个工作天内

价格

微生物 API 市场成长与趋势：

Grand View Research最新报告显示，预计到2030年，全球微生物原料药市场规模将达到961.1亿美元，2023年至2030年复合年增长率为6.66%。

这种增长是由对可治疗危及生命的疾病的抗体、蛋白质、小分子和相关产品的需求不断增长所推动的。此外，增加生产创新疫苗和联合疗法的研发工作预计将推动市场成长。

微生物经过发酵以产生次级代谢物。这些微生物能够将经济的碳源（淀粉、葡萄糖、蔗糖）和氮源（棉籽粉、大豆粉、蛋白胨）转化为有用的中间体和微生物原料药（维生素、抗生素、胺基酸等）。环境有调整。 API是药物中的生物/合成活性成分，用于治疗、检测、缓解和预防中枢神经系统疾病、糖尿病、肿瘤、神经系统疾病、心血管疾病和呼吸系统疾病等疾病。原料药的製造技术包括化学合成、重组DNA、发酵、分离及天然物回收。

对于失去排他性的小分子和生技药品，製药公司面临高昂的定价压力、竞争加剧和价格边际收益下降。活性药物原料药是所有成品药的治疗核心，占小分子药品总成本的 30%，生物相似药和学名药的成本高达 55%。因此，原料药製造商不断面临提高性能同时降低价格的挑战。

儘管微生物发酵有着悠久的历史，但它对于製药公司来说是一种高效且经济的缩短生产时间的手段。发酵过程与现代分子生物学技术和基因工程工具相结合，提高了药物的安全性和有效性。分子生物学和合成生物学不断进步的倡议对创新生物合成途径的发展产生了重大影响。此外，微生物发酵技术不仅在製药工业中得到应用，而且在食品生产、生物催化酶、农业和其他各个领域都有应用。

市场参与者正在做出策略性努力，以满足对高效、有效的药物製剂製造能力不断增长的需求。市场参与者正专注于开拓新产品和收购区域参与者，以加强其在区域市场的地位。例如，Cytovance Biologics 于 2023 年 3 月与 Phenotype 合作开发了一种酿酒酵母菌株。此次合作预计将加强生物製药製造并提高生技药品的生产效率。此类倡议预计将推动微生物 API 市场的整体成长。

微生物 API 市场报告亮点

  • 根据宿主，哺乳动物细分市场将在 2022 年占据市场主导地位，预计在预测期内将以最快的复合年增长率成长。微生物 API 因其在治疗性抗体开发中的有效性和安全性已得到证实而被广泛采用。
  • 按类型划分，由于对基于抗体的治疗药物开发的需求不断增长，抗体细分市场将在 2022 年占据主导市场占有率。
  • 按地点划分，由于药物开发中 CDMO 和 CMO 的聘用不断增加，外包产业在 2022 年的销售额中占据最大份额。
  • 亚太地区拥有高品质的原料药生产设施，使该地区在微生物 API 市场中占据了强势地位。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章市场变数、趋势和范围

  • 市场区隔和范围
  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场趋势及展望
  • 市场动态
    • 慢性病盛行率增加
    • 对生物来源製品、胺基酸和抗生素的需求增加
    • 加大医药产业投资力度
    • 分子生物学和合成生物学的进展
  • 市场抑制因素分析
    • 与程序相关的高成本
  • 2022 年普及与成长前景图
  • 营商环境分析
    • SWOT 分析；按因素（政治/法律、经济/技术）
    • 波特五力分析

第四章 主机业务分析

  • 微生物 API 市场：宿主变异分析
  • 哺乳动物的
  • 细菌
  • 菌

第五章 类型业务分析

  • 微生物 API 市场：类型变异分析
  • 抗体
  • 胜肽
  • 蛋白质
  • 低分子
  • 疫苗

第六章基础业务分析

  • 微生物 API 市场：基础变化分析
  • 公司内部
  • 外包

第七章 最终用途业务分析

  • 微生物 API 市场：最终用途变化分析
  • 製药公司
  • 生物製药公司
  • 其他的

第8章分子商业分析

  • 微生物 API 市场：分子变异分析
  • 创新的
  • 非专利的

第九章区域业务分析

  • 2022 年和 2030 年按地区分類的微生物 API市场占有率
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第10章竞争形势

  • 公司分类
  • 策略规划
    • 新产品发布
    • 合伙
    • 获得
    • 合作
    • 资金筹措
  • 2022年主要企业市场占有率分析
  • 企业热力图分析
  • 公司简介
    • MERCK &CO., INC.
    • Topfond Pharmaceutical Co., Ltd.
    • DSM
    • CSPC Pharmaceutical Group Limited
    • KOLON LIFE SCIENCE
    • Shandong Lukang Pharmaceutical Co., Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Lonza
Product Code: GVR-4-68040-156-1

Microbial API Market Growth & Trends:

The global microbial API market size is anticipated to reach USD 96.11 billion by 2030 and display a CAGR of 6.66% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth can be attributed to the rising demand for antibodies, proteins, small molecules, and related products capable of treating life-threatening diseases. Furthermore, an increase in R&D efforts for the manufacturing of innovative vaccines and combined therapy is anticipated to propel the market growth.

Microorganisms undergo fermentation for the development of secondary metabolites. Adjustments in growth environments are made to enable these organisms to covert economical carbon sources (starch, glucose, sucrose) and nitrogen sources (cotton-seed flour, soybean flour, peptone) into useful intermediates or microbial APIs (such as vitamins, antibiotics, amino acids). APIs are the biological/synthetic active constituents of pharmaceuticals and are used to treat, detect, mitigate, and prevent diseases, including conditions such as CNS disorders, diabetes, oncology, neurological diseases, cardiovascular and respiratory disorders, and others. Some of the production techniques used for the manufacture of API include chemical synthesis, recombinant DNA, fermentation, isolation, and natural source recovery.

There is high pricing pressure, increased competition, and declining pricing margins faced by pharma companies for small molecules and biologics that have lost exclusivity. APIs, which are the therapeutic core of every finished medicinal product, account for 30% of total drug product expenses for small molecules and up to 55% for biosimilar and generics. As a result, API manufacturers are always challenged to increase performance while lowering prices.

While microbial fermentation has been in existence for a long time, it offers pharmaceutical companies an efficient and cost-effective means to reduce production timelines. When combined with contemporary molecular biology techniques and genetic engineering tools, the fermentation process enhances the safety and efficacy of medicines. Rising initiatives for advancements in molecular biology and synthetic biology have had a profound effect on the development of innovative biosynthetic pathways. Moreover, microbial fermentation techniques find applications not only in the pharmaceutical industry but also in sectors such as food production, bio catalytic enzymes, agriculture, and various other fields.

Market players are undertaking strategic initiatives to address the growing demand for efficient and effective drug formulation manufacturing capacity. Players in the market are focusing on developing new products and acquisition of regional players to strengthen their position in the regional market. For instance, in March 2023, Cytovance Biologics entered into a partnership with Phenotypeca for the development of the saccharomyces cerevisiae strain. The partnership is expected to enhance biopharmaceutical manufacturing and improve biologics production efficiency. Such initiatives are expected to propel the overall growth of the microbial API market.

Microbial API Market Report Highlights:

  • Based on host, the mammalian segment dominated the market in 2022 and is expected to grow at the fastest CAGR over the forecast period, as microbial APIs are widely adopted due to their proven efficacy and safety profile for the development of therapeutic antibodies
  • Based on type, the antibody segment held the dominant market share in 2022 due to the rising need to develop antibody-based therapeutics
  • Based on site, the outsourced segment held the largest revenue share in 2022, owing to the rising adoption of CDMOs and CMOs for drug development
  • Asia Pacific has established a strong regional position in the market for microbial API due to the presence of manufacturing facilities for high-quality APIs in the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Information Procurement
  • 1.2. Information or Data Analysis
  • 1.3. Market Scope & Segment Definition
  • 1.4. Market Model
    • 1.4.1. Market Study, By Company Market Share
    • 1.4.2. Regional Analysis

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Increasing prevalence of chronic conditions
    • 3.4.2. Increased demand for biological products, amino acids, and antibiotics
    • 3.4.3. Increasing investment in the pharmaceutical industry
    • 3.4.4. Advances in molecular biology and synthetic biology
  • 3.5. Market Restraint Analysis
    • 3.5.1. High cost associated with the procedure
  • 3.6. Penetration and Growth Prospect Mapping 2022
  • 3.7. Business Environment Analysis
    • 3.7.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.7.2. Porter's Five Forces Analysis

Chapter 4. Host Business Analysis

  • 4.1. Microbial API Market: Host Movement Analysis
  • 4.2. Mammalian
    • 4.2.1. Mammalian Market, 2018 - 2030 (USD Million)
  • 4.3. Bacterial
    • 4.3.1. Bacterial Market, 2018 - 2030 (USD Million)
  • 4.4. Fungal
    • 4.4.1. Fungal Market, 2018 - 2030 (USD Million)

Chapter 5. Type Business Analysis

  • 5.1. Microbial API Market: Type Movement Analysis
  • 5.2. Antibody
    • 5.2.1. Antibody Market, 2018 - 2030 (USD Million)
  • 5.3. Peptide
    • 5.3.1. Peptide Market, 2018 - 2030 (USD Million)
  • 5.4. Protein
    • 5.4.1. Protein Market, 2018 - 2030 (USD Million)
  • 5.5. Small Molecule
    • 5.5.1. Small Molecule Market, 2018 - 2030 (USD Million)
  • 5.6. Vaccine
    • 5.6.1. Vaccine Market, 2018 - 2030 (USD Million)

Chapter 6. Site Business Analysis

  • 6.1. Microbial API Market: Site Movement Analysis
  • 6.2. In-house
    • 6.2.1. In-house Market, 2018 - 2030 (USD Million)
  • 6.3. Outsourced
    • 6.3.1. Outsourced Market, 2018 - 2030 (USD Million)

Chapter 7. End-use Business Analysis

  • 7.1. Microbial API Market: End-use Movement Analysis
  • 7.2. Pharmaceutical Companies
    • 7.2.1. Pharmaceutical Companies Market, 2018 - 2030 (USD Million)
  • 7.3. Biopharmaceutical Companies
    • 7.3.1. Biopharmaceutical Companies Market, 2018 - 2030 (USD Million)
  • 7.4. Others
    • 7.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Molecule Business Analysis

  • 8.1. Microbial API Market: Molecule Movement Analysis
  • 8.2. Innovative
    • 8.2.1. Innovative Market, 2018 - 2030 (USD Million)
  • 8.3. Generic
    • 8.3.1. Generic Market, 2018 - 2030 (USD Million)

Chapter 9. Regional Business Analysis

  • 9.1. Microbial API Market Share By Region, 2022 & 2030
  • 9.2. North America
    • 9.2.1. SWOT Analysis
    • 9.2.2. North America Microbial API Market, 2018 - 2030 (USD Million)
    • 9.2.3. U.S.
      • 9.2.3.1. Key Country Dynamics
      • 9.2.3.2. Target Disease Prevalence
      • 9.2.3.3. Competitive Scenario
      • 9.2.3.4. Regulatory Framework
      • 9.2.3.5. Reimbursement Scenario
      • 9.2.3.6. U.S. Microbial API Market, 2018 - 2030 (USD MILLION)
    • 9.2.4. Canada
      • 9.2.4.1. Key Country Dynamics
      • 9.2.4.2. Target Disease Prevalence
      • 9.2.4.3. Competitive Scenario
      • 9.2.4.4. Regulatory Framework
      • 9.2.4.5. Reimbursement Scenario
      • 9.2.4.6. Canada Microbial API Market, 2018 - 2030 (USD Million)
  • 9.3. Europe
    • 9.3.1. SWOT Analysis
    • 9.3.2. Europe Microbial API Market, 2018 - 2030 (USD Million)
    • 9.3.3. Germany
      • 9.3.3.1. Key Country Dynamics
      • 9.3.3.2. Target Disease Prevalence
      • 9.3.3.3. Competitive Scenario
      • 9.3.3.4. Regulatory Framework
      • 9.3.3.5. Reimbursement Scenario
      • 9.3.3.6. Germany Microbial API Market, 2018 - 2030 (USD Million)
    • 9.3.4. UK
      • 9.3.4.1. Key Country Dynamics
      • 9.3.4.2. Target Disease Prevalence
      • 9.3.4.3. Competitive Scenario
      • 9.3.4.4. Regulatory Framework
      • 9.3.4.5. Reimbursement Scenario
      • 9.3.4.6. UK Microbial API Market, 2018 - 2030 (USD Million)
    • 9.3.5. France
      • 9.3.5.1. Key Country Dynamics
      • 9.3.5.2. Target Disease Prevalence
      • 9.3.5.3. Competitive Scenario
      • 9.3.5.4. Regulatory Framework
      • 9.3.5.5. Reimbursement Scenario
      • 9.3.5.6. France Microbial API Market, 2018 - 2030 (USD Million)
    • 9.3.6. Italy
      • 9.3.6.1. Key Country Dynamics
      • 9.3.6.2. Target Disease Prevalence
      • 9.3.6.3. Competitive Scenario
      • 9.3.6.4. Regulatory Framework
      • 9.3.6.5. Reimbursement Scenario
      • 9.3.6.6. Italy Microbial API Market, 2018 - 2030 (USD Million)
    • 9.3.7. Spain
      • 9.3.7.1. Key Country Dynamics
      • 9.3.7.2. Target Disease Prevalence
      • 9.3.7.3. Competitive Scenario
      • 9.3.7.4. Regulatory Framework
      • 9.3.7.5. Reimbursement Scenario
      • 9.3.7.6. Spain Microbial API Market, 2018 - 2030 (USD Million)
    • 9.3.8. Denmark
      • 9.3.8.1. Key Country Dynamics
      • 9.3.8.2. Target Disease Prevalence
      • 9.3.8.3. Competitive Scenario
      • 9.3.8.4. Regulatory Framework
      • 9.3.8.5. Reimbursement Scenario
      • 9.3.8.6. Denmark Microbial API Market, 2018 - 2030 (USD Million)
    • 9.3.9. Sweden
      • 9.3.9.1. Key Country Dynamics
      • 9.3.9.2. Target Disease Prevalence
      • 9.3.9.3. Competitive Scenario
      • 9.3.9.4. Regulatory Framework
      • 9.3.9.5. Reimbursement Scenario
      • 9.3.9.6. Sweden Microbial API Market, 2018 - 2030 (USD Million)
    • 9.3.10. Norway
      • 9.3.10.1. Key Country Dynamics
      • 9.3.10.2. Target Disease Prevalence
      • 9.3.10.3. Competitive Scenario
      • 9.3.10.4. Regulatory Framework
      • 9.3.10.5. Reimbursement Scenario
      • 9.3.10.6. Norway Microbial API Market, 2018 - 2030 (USD Million)
  • 9.4. Asia Pacific
    • 9.4.1. SWOT Analysis
    • 9.4.2. Asia Pacific Microbial API Market, 2018 - 2030 (USD Million)
    • 9.4.3. Japan
      • 9.4.3.1. Key Country Dynamics
      • 9.4.3.2. Target Disease Prevalence
      • 9.4.3.3. Competitive Scenario
      • 9.4.3.4. Regulatory Framework
      • 9.4.3.5. Reimbursement Scenario
      • 9.4.3.6. Japan Microbial API Market, 2018 - 2030 (USD Million)
    • 9.4.4. China
      • 9.4.4.1. Key Country Dynamics
      • 9.4.4.2. Target Disease Prevalence
      • 9.4.4.3. Competitive Scenario
      • 9.4.4.4. Regulatory Framework
      • 9.4.4.5. Reimbursement Scenario
      • 9.4.4.6. China Microbial API Market, 2018 - 2030 (USD Million)
    • 9.4.5. India
      • 9.4.5.1. Key Country Dynamics
      • 9.4.5.2. Target Disease Prevalence
      • 9.4.5.3. Competitive Scenario
      • 9.4.5.4. Regulatory Framework
      • 9.4.5.5. Reimbursement Scenario
      • 9.4.5.6. India Microbial API Market, 2018 - 2030 (USD Million)
    • 9.4.6. South Korea
      • 9.4.6.1. Key Country Dynamics
      • 9.4.6.2. Target Disease Prevalence
      • 9.4.6.3. Competitive Scenario
      • 9.4.6.4. Regulatory Framework
      • 9.4.6.5. Reimbursement Scenario
      • 9.4.6.6. South Korea Microbial API Market, 2018 - 2030 (USD Million)
    • 9.4.7. Australia
      • 9.4.7.1. Key Country Dynamics
      • 9.4.7.2. Target Disease Prevalence
      • 9.4.7.3. Competitive Scenario
      • 9.4.7.4. Regulatory Framework
      • 9.4.7.5. Reimbursement Scenario
      • 9.4.7.6. Australia Microbial API Market, 2018 - 2030 (USD Million)
    • 9.4.8. Thailand
      • 9.4.8.1. Key Country Dynamics
      • 9.4.8.2. Target Disease Prevalence
      • 9.4.8.3. Competitive Scenario
      • 9.4.8.4. Regulatory Framework
      • 9.4.8.5. Reimbursement Scenario
      • 9.4.8.6. Thailand Microbial API Market, 2018 - 2030 (USD Million)
  • 9.5. Latin America
    • 9.5.1. SWOT Analysis
    • 9.5.2. Latin America Microbial API Market, 2018 - 2030 (USD Million)
    • 9.5.3. Brazil
      • 9.5.3.1. Key Country Dynamics
      • 9.5.3.2. Target Disease Prevalence
      • 9.5.3.3. Competitive Scenario
      • 9.5.3.4. Regulatory Framework
      • 9.5.3.5. Reimbursement Scenario
      • 9.5.3.6. Brazil Microbial API Market, 2018 - 2030 (USD Million)
    • 9.5.4. Mexico
      • 9.5.4.1. Key Country Dynamics
      • 9.5.4.2. Target Disease Prevalence
      • 9.5.4.3. Competitive Scenario
      • 9.5.4.4. Regulatory Framework
      • 9.5.4.5. Reimbursement Scenario
      • 9.5.4.6. Mexico Microbial API Market, 2018 - 2030 (USD Million)
    • 9.5.5. Argentina
      • 9.5.5.1. Key Country Dynamics
      • 9.5.5.2. Target Disease Prevalence
      • 9.5.5.3. Competitive Scenario
      • 9.5.5.4. Regulatory Framework
      • 9.5.5.5. Reimbursement Scenario
      • 9.5.5.6. Argentina Microbial API Market, 2018 - 2030 (USD Million)
  • 9.6. MEA
    • 9.6.1. SWOT Analysis
    • 9.6.2. MEA Microbial API Market, 2018 - 2030 (USD Million)
    • 9.6.3. South Africa
      • 9.6.3.1. Key Country Dynamics
      • 9.6.3.2. Target Disease Prevalence
      • 9.6.3.3. Competitive Scenario
      • 9.6.3.4. Regulatory Framework
      • 9.6.3.5. Reimbursement Scenario
      • 9.6.3.6. South Africa Microbial API Market, 2018 - 2030 (USD Million)
    • 9.6.4. Saudi Arabia
      • 9.6.4.1. Key Country Dynamics
      • 9.6.4.2. Target Disease Prevalence
      • 9.6.4.3. Competitive Scenario
      • 9.6.4.4. Regulatory Framework
      • 9.6.4.5. Reimbursement Scenario
      • 9.6.4.6. Saudi Arabia Microbial API Market, 2018 - 2030 (USD Million)
    • 9.6.5. UAE
      • 9.6.5.1. Key Country Dynamics
      • 9.6.5.2. Target Disease Prevalence
      • 9.6.5.3. Competitive Scenario
      • 9.6.5.4. Regulatory Framework
      • 9.6.5.5. Reimbursement Scenario
      • 9.6.5.6. UAE Microbial API Market, 2018 - 2030 (USD Million)
    • 9.6.6. Kuwait
      • 9.6.6.1. Key Country Dynamics
      • 9.6.6.2. Target Disease Prevalence
      • 9.6.6.3. Competitive Scenario
      • 9.6.6.4. Regulatory Framework
      • 9.6.6.5. Reimbursement Scenario
      • 9.6.6.6. Kuwait Microbial API Market, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Company Categorization
  • 10.2. Strategy Mapping
    • 10.2.1. New Product Launch
    • 10.2.2. Partnerships
    • 10.2.3. Acquisition
    • 10.2.4. Collaboration
    • 10.2.5. Funding
  • 10.3. Key Company Market Share Analysis, 2022
  • 10.4. Company Heat Map Analysis
  • 10.5. Company Profiles
    • 10.5.1. MERCK & CO., INC.
      • 10.5.1.1. Company overview
      • 10.5.1.2. Financial performance
      • 10.5.1.3. Product benchmarking
      • 10.5.1.4. Strategic initiatives
    • 10.5.2. Topfond Pharmaceutical Co., Ltd.
      • 10.5.2.1. Company overview
      • 10.5.2.2. Financial performance
      • 10.5.2.3. Product benchmarking
      • 10.5.2.4. Strategic initiatives
    • 10.5.3. DSM
      • 10.5.3.1. Company overview
      • 10.5.3.2. Financial performance
      • 10.5.3.3. Product benchmarking
      • 10.5.3.4. Strategic initiatives
    • 10.5.4. CSPC Pharmaceutical Group Limited
      • 10.5.4.1. Company overview
      • 10.5.4.2. Financial performance
      • 10.5.4.3. Product benchmarking
      • 10.5.4.4. Strategic initiatives
    • 10.5.5. KOLON LIFE SCIENCE
      • 10.5.5.1. Company overview
      • 10.5.5.2. Financial performance
      • 10.5.5.3. Product benchmarking
      • 10.5.5.4. Strategic initiatives
    • 10.5.6. Shandong Lukang Pharmaceutical Co., Ltd.
      • 10.5.6.1. Company overview
      • 10.5.6.2. Financial performance
      • 10.5.6.3. Product benchmarking
      • 10.5.6.4. Strategic initiatives
    • 10.5.7. Teva Pharmaceutical Industries Ltd.
      • 10.5.7.1. Company overview
      • 10.5.7.2. Financial performance
      • 10.5.7.3. Product benchmarking
      • 10.5.7.4. Strategic initiatives
    • 10.5.8. Lonza
      • 10.5.8.1. Company overview
      • 10.5.8.2. Financial performance
      • 10.5.8.3. Product benchmarking
      • 10.5.8.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 3 Global Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 4 Global Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 5 Global Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 6 Global Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 7 Global Microbial API Market, by Region, 2018 - 2030 (USD Million)
  • Table 8 North America Microbial API Market, by Country, 2018 - 2030 (USD Million)
  • Table 9 North America Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 10 North America Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 11 North America Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 12 North America Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 13 North America Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 14 U.S. Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 15 U.S. Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 16 U.S. Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 17 U.S. Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 18 U.S. Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 19 Canada Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 20 Canada Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 21 Canada Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 22 Canada Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 23 Canada Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 24 Europe Microbial API Market, by Country, 2018 - 2030 (USD Million)
  • Table 25 Europe Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 26 Europe Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 27 Europe Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 28 Europe Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 29 Europe Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 30 Germany Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 31 Germany Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 32 Germany Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 33 Germany Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 34 Germany Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 35 UK Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 36 UK Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 37 UK Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 38 UK Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 39 UK Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 40 France Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 41 France Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 42 France Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 43 France Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 44 France Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 45 Italy Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 46 Italy Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 47 Italy Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 48 Italy Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 49 Italy Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 50 Spain Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 51 Spain Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 52 Spain Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 53 Spain Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 54 Spain Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 55 Denmark Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 56 Denmark Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 57 Denmark Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 58 Denmark Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 59 Denmark Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 60 Sweden Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 61 Sweden Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 62 Sweden Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 63 Sweden Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 64 Sweden Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 65 Norway Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 66 Norway Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 67 Norway Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 68 Norway Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 69 Norway Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 70 Asia Pacific Microbial API Market, by Country, 2018 - 2030 (USD Million)
  • Table 71 Asia Pacific Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 72 Asia Pacific Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 73 Asia Pacific Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 74 Asia Pacific Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 75 Asia Pacific Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 76 China Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 77 China Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 78 China Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 79 China Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 80 China Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 81 Japan Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 82 Japan Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 83 Japan Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 84 Japan Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 85 Japan Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 86 India Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 87 India Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 88 India Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 89 India Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 90 India Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 91 South Korea Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 92 South Korea Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 93 South Korea Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 94 South Korea Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 95 South Korea Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 96 Australia Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 97 Australia Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 98 Australia Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 99 Australia Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 100 Australia Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 101 Thailand Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 102 Thailand Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 103 Thailand Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 104 Thailand Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 105 Thailand Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 106 Latin America Microbial API Market, by Country, 2018 - 2030 (USD Million)
  • Table 107 Latin America Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 108 Latin America Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 109 Latin America Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 110 Latin America Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 111 Latin America Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 112 Brazil Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 113 Brazil Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 114 Brazil Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 115 Brazil Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 116 Brazil Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 117 Mexico Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 118 Mexico Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 119 Mexico Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 120 Mexico Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 121 Mexico Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 122 Argentina Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 123 Argentina Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 124 Argentina Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 125 Argentina Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 126 Argentina Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 127 Middle East & Africa Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 128 Middle East & Africa Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 129 Middle East & Africa Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 130 Middle East & Africa Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 131 Middle East & Africa Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 132 South Africa Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 133 South Africa Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 134 South Africa Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 135 South Africa Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 136 South Africa Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 137 Saudi Arabia Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 138 Saudi Arabia Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 139 Saudi Arabia Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 140 Saudi Arabia Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 141 Saudi Arabia Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 142 UAE Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 143 UAE Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 144 UAE Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 145 UAE Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 146 UAE Microbial API Market, by Molecule, 2018 - 2030 (USD Million)
  • Table 147 Kuwait Microbial API Market, by Host, 2018 - 2030 (USD Million)
  • Table 148 Kuwait Microbial API Market, by Type, 2018 - 2030 (USD Million)
  • Table 149 Kuwait Microbial API Market, by Site, 2018 - 2030 (USD Million)
  • Table 150 Kuwait Microbial API Market, by End-use, 2018 - 2030 (USD Million)
  • Table 151 Kuwait Microbial API Market, by Molecule, 2018 - 2030 (USD Million)